Regulation of dendritic cell system by tumor

Cancer Research, Therapy and Control

Volumn 11, Issue 1, 2001, Pages 65-78

  Shurin, Michael R ^a   Gabrilovich, Dmitry I ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; CD34+ cells; Dendritic Cells; Immunotherapy

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0035066186     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Alavena P., Piemonti L., Longoni D., Bernasconi S., Stoppacciaro A., Ruco L., Mantovani A. (1998). IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol., 28, 359-363.
2. Ambe K., Mori M., Enjoji M. (1989). S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer, 63, 496-503.
3. Armstrong T.D., Pulaski B.A., Ostrand-Rosenberg S. (1998). Tumor antigen presentation: changing the rules. Cancer Immunol Immunother., 46, 70-4.
4. Banchereau J., Steinman R.M. (1998). Dendritic cells and the control of immunity. Nature., 392, 245-252.
5. Becker Y. (1992). Anticancer role of dendritic cells (DC) in human and experimental cancers-A review. Anticancer Research, 12, 511-520.
6. Beissert S., Hosoi J., Grabbe S., Asahina A., Granstein R.D. (1995). IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J. Immunol., 154, 1280-1286.
7. Benjamin D., Knobloch T.J., Dayton M.A. (1992). Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10 [see comments). Blood, 80, 1289-98.
8. Bethwaite P.B., Holloway L.J., Thornton A., Delahunt B. (1996). Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study. Pathology, 28, 321-7.
9. Bigotti G., Coli A., Castagnola D. (1991). Distribution of Langerhans cells and HLA class II molecules in prostatic carcinomas of different histopathological grade. Prostate, 19, 73-87.
10. Buelens C., Verhasselt V., De Groote D., Thielemans K., Goldman M., Willems F. (1997). Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol., 27, 756-62.
11. Caux C., Massacrier C., Vanbervliet B., Barthelemy C., Liu Y.J., Banchereau J. (1994). Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Intern. Immunol., 6, 1177-1185.
12. Chaux P., Favre N., Martin M., F. M. (1997). Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. International Journal of Cancer, 72, 619-624.
13. Chen H.D., Zhao Y.M., Sun G., Yang C.Y. (1989). Occurrence of Langerhans cells and expression of class II antigens on keratinocytes in malignant and benign epithelial tumors of the skin: an immunohistopathologic study with monoclonal antibodies. J Am Acad Dermatol., 20, 1007-14.
14. Chen L., Linsley P.S., Hellstrom K.E. (1993). Costimulation of T cells for tumor immunity. Immunol Today, 14, 483-6.
15. Chen Q., Daniel V., Maher D.W., Hersey P. (1994). Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cance., 56, 755-60.
16. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J.Y. (1997). The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today, 18, 493-7.
17. Cohen P.J., Cohen P.A., Rosenberg S.A., Katz S.I., Mule J.J. (1994). Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol., 24, 315-319.
18. Corazza F., Beguin Y., Bergmann P., Andre M., Ferster A., Devalck C., Fondu P., Buyse M., Sariban E. (1998). Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood, 92, 1793-8.
19. Ellis L.M., Fidler I.J. (1996). Angiogenesis and metastasis. Eur. J. Cancer, 32A, 2451-2460.
20. Enk A.M., Angeloni V.L., Udey M.C., Katz S.I. (1993). Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol., 151, 2390-2398.
21. Enk A.M., Jonuleit H., Saloga J., Knop J. (1997). Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer., 73, 309-16.
22. Esche C., Gambotto A., Satoh Y., Gerein V., Robbins P.D., Watkins S.C., Lotze M.T., Shurin M.R. (1999a). CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. European Journal of Immunology, 29, 2148-2155.
23. Esche C., Lokshin A., Shurin G.V., Gastman B.R., Rabinowich H., Watkins S.C., Lotze M.T., Shurin M.T. (1999b). Tumor's other immune targets: dendritic cells. J. Leuk. Biol., 66, 336-344.
24. Esche C., Shurin M.R., Lotze M.T. (1997). B16 melanoma induces downregulation of beta2 integrin and ICAM-1 expression on murine dendritic cells. J. Invest. Dermatol., 108, 640.
25. Esche C., Shurin M.R., Lotze M.T. (1999c). The use of dendritic cells for cancer vaccination. Current Opinion in Molecular Therapeutics., 1, 72-81.
26. Esche C., Subbotin V., Maliszewski C., Lotze M., Shurin M. (1998). FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res., 58, 380-383.
27. Facchetti F., de Wolf-Peeters C., de Greet' H., Desmet V.J. (1984). Langerhans cells in various benign and malignant pigment-cell lesions of the skin. Arch Dermatol Res., 276, 283-7.
28. Ferrara N., Smyth D.T. (1997). The biology of vascular endothelial growth factor. Endocr. Rev., 18, 4-25.
29. Fiumara A., Belfiore A., Russo G., Salomone E., Santonocito G.M., Ippolito O., Vigneri R., Gangemi P. (1997). In situ evidence of neoplastic cell phagocytosis by macrophages in papillary thyroid cancer. J Clin Endocrinol Metab., 82, 1615-20.
30. Flamand V., Sornasse T., Thielemans K., Demanet C., Bakkus M., Bazin H., Tielemans F., Leo O., Urbain J., M. M. (1994). Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol., 24, 605-610.
31. Fox S.B., Jones M., Dunnill M.S., Gatter K.C., Mason D.Y. (1989). Langerhans cells in human lung tumours: an immunohistological study. Histopathology, 14, 269-75.
32. Furihata M., Ohtsuki Y. (1991). Immunohistochemical characterization of HLA-DR-antigen positive dendritic cells in phaeochromocytomas and paragangliomas as a prognostic marker. Virchows Arch A Pathol Anat Histopathol., 418, 33-9.
33. Furukawa T., Watanabe S., Kodama T., Sato Y., Shimosato Y., Suemasu K. (1985). T-zone histiocytes in adenocarcinoma of the lung in relation to postoperative prognosis. Cancer, 56, 2651-6.
34. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., Carbone D.P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 92, 4150-66.
35. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. (1996a). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published erratum appears in Nat Med 1996 Nov;2(11):1267]. Nat Med., 2, 1096-103.
36. Gabrilovich D.I., Ciernik I.F., Carbone D.P. (1996b). Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol., 170, 101-10.
37. Gabrilovich D.I., Corak J., Ciernik I.F., Kavanaugh D., Carbone D.P. (1997a). Decreased antigen presentation by dendritic-cells in patients with breast cancer. Clin. Cancer Res., 3, 483-490.
38. Gabrilovich D.I., Cunningham H.T., Carbone D.P. (1997b). IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunoth., 19, 414-418.
39. Gabrilovich D.I., Nadaf S., Corak J., Berzofsky J.A., Carbone D.P. (1996c). Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cellular Immunology, 170, 111-120.
40. Garcia-Plata D., Lessana-Leibowitch M., Palangie A., Gulliemette J., Sedel D., Mendez L., Mozos E. (1995). Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. Invasion Metastasis, 15, 125-34.
41. Gastl G.A., Abrams J.S., Nanus D.M., Oosterkamp R., Silver J., Liu F., Chen M., Albino A.P., Bander N.H. (1993). Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer., 55, 96-101.
42. Gatter K.C., Morris H.B., Roach B., Mortimer P., Fleming K.A., Mason D.Y. (1984). Langerhans' cells and T cells in human skin tumours: an immunohistological study. Histopathology. 8, 229-44.
43. Goldman S.A., Baker E., Weyant R.J., Clarke M.R., Myers J.N., Lotze M.T. (1998). Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg., 124, 641-6.
44. Griffith T.S., Ferguson T.A. (1997). The role of FasL-induced apoptosi.s in immune privilege [published erratum appears in Immunol Today 1997 Jul; 18(7):361]. Immunol Today. 18, 240-4.
45. Harding F.A., McArthur J.G., Gross J.A., Raulet D.H., Allison J.P. (1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature, 356, 607-9.
46. Hart D.N.J. (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood. 90, 3245-3287.
47. Hsu F., Benike C., Fagnoni F., Liles T.M., Czerwinsky D., Taidi B., Engleman E.G., Levy R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Medicine., 2, 52-58.
48. Huang A.Y.C., Golumbek P., Ahmadzadeh M., Jaffee E., Pardoll D., Levitsky H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science., 264, 961-965.
49. Huang M., Sharma S., Mao J.T., Dubinett S.M. (1996). Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol., 157, 5512-20.
50. Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S.M. (1995). Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res., 55, 3847-53.
51. Hubbard W.C., Alley M.C., McLemore T.L., Boyd M.R. (1988). Profiles of prostaglandin biosynthesis in sixteen established cell lines derived from human lung, colon, prostate, and ovarian tumors. Cancer Res., 48, 4770-5.
52. Ikeguchi M., Ikeda M., Tatebe S., Maeta M., Kaibara N. (1998). Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep., 5, 1185-9.
53. Imai Y., Yamakawa M. (1993). Dendritic cells in esophageal cancer and lymph node tissues. In Vivo, 7, 239-48.
54. Ishida T., Oyama T., Carbone D., Gabrilovich D.I. (1998). Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hematopoietic progenitors. J. Immunol., 161.
55. Jasani B., Navabi H., Adams M., Evans A., Mason M. (1998). Serum dependent downregulation of CD1a expression and specific CTL priming activity in human dendritic cells. Proc. Amer. Assoc. Cancer Res., 30, 611.
56. Kalinski P., Hilkens C.M., Snijdewint F.G., Kapsenberg M.L. (1995). Prostaglandin E2 prevents the generation of CD1 + dendritic cells. Immunol., 86, 15.
57. Kambayashi T., Alexander H.R., Fong M., Strassmann G. (1995). Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol., 154, 3383-90.
58. Kaucic K., Grovas A., Li R., Quinones R., Ladisch S. (1994). Modulation of human myelopoiesis by human gangliosides. Exp Hematol., 22, 52-9.
59. Kavanaugh D.Y., Carbone D.P. (1996). Immunologic dysfunction in cancer. Hematol Oncol Clin North Am., 10, 927-51.
60. Kawashima I., Ozawa H., Kotani M., Suzuki M., Kawano T., Gomibuchi M., Tai T. (1993). Characterization of ganglioside expression in human melanoma cells: immunological and biochemical analysis. J Biochem (Tokyo)., 114, 186-93.
61. Kiertscher S.M., Dubinett S.M., Roth M.D. (1998). Tumor-derived factors induce apoptosis in developing dendritic cells. Journal of Leukocyte Biology, Suppl. 2, 47A.
62. Kim J., Modlin R.L., Moy R.L., Dubinett S.M., McHugh T., Nickoloff B.J., Uyemura K. (1995). IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol., 155, 2240-7.
63. Knight S.C., Stagg A.J. (1993). Antigen-presenting cell types. Curr Opin Immunol., 5, 374-382.
64. Kornstein M.J., Brooks J.S., Elder D.E. (1983). Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res., 43, 2749-53.
65. Ladisch S. (1987). Tumor cell gangliosides. Adv Pediatr., 34, 45-58.
66. Ladisch S., Wu Z.L., Feig S., Ulsh L., Schwanz E., Floutsis G., Wiley F., Lenarsky C., Seeger R. (1987). Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer., 39, 73-6.
67. Lattime E.C., Mastrangelo M.J., Bagasra O., Li W., Berd D. (1995). Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother., 41, 151-6.
68. Lipscomb M.F., Pollard A.M., Yates J.L. (1993). A role for TGF-beta in the suppression by murine bronchoalveolar cells of lung dendritic cell initiated immune responses. Reg Immunol., 5, 151-7.
69. Lopez D.M., Lopez-Cepero M., Watson G.A., Ganju A., Sotomayor E., Fu Y.X. (1991). Modulation of the immune system by mammary tumor-derived factors. Cancer Invest., 9, 643-53.
70. Lotze M.T. (1997). Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment]. Ann Surg., 226, 1-5.
71. Lotze M.T., Shurin M., Davis I., Amoscato A., Storkus W.J. (1997). Dendritic cell based therapy of cancer. Adv Exp Med Biol., 417, 551-69.
72. Lynch D., Andreasen A., Maraskovsky E., Whitmore J., Miller R., Schuh J. (1997). Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3, 625-631.
73. Maraskovsky E., Brasel K., Teepe M., Roux E.R., Lyman S.D., Shortman K., McKenna H.J. (1996). Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 ligand -treated mice: multiple dendritic cells subpopulations identified. J. Exp. Med., 184, 1953-1961.
74. Marquina G., Waki H., Fernandez L.E., Kon K., Carr A., Valiente O., Perez R., Ando S. (1996). Gangliosides expressed in human breast cancer. Cancer Res., 56, 5165-71.
75. Matsuda H., Mori M., Tsujitani S., Ohno S., Kuwano H., Sugimachi K. (1990). Immunohistochemical evaluation of squamous cell carcinoma antigen and S- 100 protein-positive cells in human malignant esophageal tissues. Cancer., 65, 2261-5.
76. Matzinger P. (1994). Tolerance, danger, and the extended family. Annu Rev Immunol., 12, 991-1045.
77. Mayordomo J.I., Zorina T., Storkus W.J., Celluzzi C., Falo L.D., Melief C.J., Ildstad T., Kast W.M., DeLeo A.B., Lotze M.T. (1995). Bone-marrow derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine, 1, 1297-1302.
78. McGovern V.J. (1975). Spontaneous regression of melanoma. Pathology., 7, 91-9.
79. McLemore T.L., Hubbard W.C., Litterst C.L., Liu M.C., Miller S., McMahon N.A., Eggleston J.C., Boyd M.R. (1988). Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res., 48, 3140-7.
80. Meckenstock G., Aul C., Hildebrandt B., Heyll A., Germing U., Wehmeier A., Giagounidis A., Suedhoff T., Burk M., Soehngen D., Schneider W. (1998). Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance [published erratum appears in Leuk Lymphoma 1998 Nov;31(5-6):following 623]. Leuk Lymphoma. 29, 523-31.
81. Meissner K., Loning T., Rehpenning W. (1993). Epidermal Langerhans cells and prognosis of patients with mycosis fungoides and Sezary syndrome. In Vivo, 7, 277-80.
82. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., Blay J.Y. (1998). Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: Role of interleukin-6 and macrophage-colony-stimuating factor. Blood, 92, 4778-4791.
83. Merritt W.D., Der-Minassian V., Reaman G.H. (1994). Increased GD3 ganglioside in plasma of children with T-cell acute lymphoblastic leukemia. Leukemia. 8, 816-22.
84. Mitra R.S., Judge T.A., Nestle F.O., Turka L.A., Nickoloff B.J. (1995). Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol., 154, 2668-77.
85. Morrison W.J., Offner H., Vandenbark A.A. (1989). Specific ganglioside binding to receptor sites on T lymphocytes that couple to ganglioside-induced decrease of CD4 expression. Life Sci., 45, 1219-26.
86. Nakagomi H., Pisa P., Pisa E., Yamamoto Y., Halapi E., Backlin K., Juhlin C., Kiessling R. (1995). Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Intern. J. Cancer, 63, 366-371.
87. Nakajima T., Kodama T., Tsumuraya M., Shimosato Y., Kameya T. (1985). S-100 protein-positive Langerhans cells in various human lung cancers, especially in peripheral adenocarcinomas. Virchows Arch A Pathol Anat Histopathol., 407, 177-89.
88. Nakano T., Oka K., Arai T., Morita S., Tsunemoto H. (1989). Prognostic significance of Langerhans' cell infiltration in radiation therapy for squamous cell carcinoma of the uterine cervix. Arch Pathol Lab Med., 113, 507-11.
89. Nestle F.O., Alijagic S., Gilliet M., Sun Y.S., Grabbe S., Dummer R., Burg G., Schadendorf D. (1998). Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells. Nat. Med., 4, 328-332.
90. Nestle P.O., Burg G., Pah J., Wrone-Smith T., Nickoloff B.J. (1997). Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol., 150, 641-51.
91. Nestor M.S., Cochran A.J. (1987). Identification and quantification of subsets of mononuclear inflammatory cells in melanocytic and other human tumors. Pigment Cell Res., 1, 22-7.
92. Nikcevich D.A., Young M.R., Ellis N.K., Newby M., Wepsic H.T. (1986). Stimulation of hematopoiesis in untreated and cyclophosphamide treated mice by the inhibition of prostaglandin synthesis. J Immunopharmacol, 8, 299-313.
93. Noguchi Y., Richards E.C., Chen Y-T., Old L. (1995). Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA., 92, 2219-2223.
94. Nomori H., Watanabe S., Nakajima T., Shimosato Y., Kameya T. (1986). Histiocytes in nasopharyngeal carcinoma in relation to prognosis. Cancer, 57, 100-5.
95. Okuyama T., Maehara Y., Kakeji Y., Tsuijitani S., Korenaga D., Sugimachi K. (1998). Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer. 82, 1468-75.
96. Paglia P., Guzman C.A. (1998). Keeping the immune system alerted against cancer. Cancer Immunol Immunother., 46, 88-92.
97. Peguet Navarro J., Moulon C., Caux C., Dalbiez-Gauthier C., Banchereau J., Schmitt D. (1994). lnterleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur. J. Immunol., 24, 884-889.
98. Pelus L.M., Gentile P.S. (1988). In vivo modulation of myelopoiesis by prostaglandin E2. III. Induction of suppressor cells in marrow and spleen capable of mediating inhibition of CFU-GM proliferation. Blood, 71, 1633-40.
99. Pelus L.M., Ottmann O.G., Nocka K.H. (1988). Synergistic inhibition of human marrow granulocyte-macrophage progenitor cells by prostaglandin E and recombinant interferon-alpha, - beta, and -gamma and an effect mediated by tumor necrosis factor. J Immunol., 140, 479-84.
100. Peron J., Esche C., Subbotin V., Maliszewski C., Lotze M., Shurin M. (1998). FLT3-ligand administration inhibits liver metastases-role of NK cells. J. Immunol., 161, 6164-6170.
101. Pisa P., Halapi E., Pisa E.K., Gerdin E., Hising C., Bucht A., Gerdin B., Kiessling R. (1992). Selective expression of interleukin 10. Interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci U S A, 89, 7708-12.
102. Poppema S., Brocker E.B., de Leij L., Terbrack D., Visscher T., Ter Haar A., Macher E., The T.H., Sorg C. (1983). In situ analysis of the inononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol., 51, 77-82.
103. Reiser H., Freeman G.J., Razi-Wolf Z., Gimmi C.D., Benacerraf B., Nadler L.M. (1992). Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci U S A, 89, 271-5.
104. Saito H., Tsujitani S., Ikeguchi M., Maeta M., Kaibara N. (1998). Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer. 78, 1573-7.
105. Saito M. (1993). Bioactive gangliosides: differentiation inducers for hematopoietic cells and their mechanism(s) of actions. Adv Lipid Res., 25, 303-27.
106. Schroder S., Schwarz W., Rehpenning W., Loning T., Bocker W. (1988). Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol., 89, 295-300.
107. Shurin M.R. (1996). Dendritic cells presenting tumor antigen. Cancer Immunol Immunother., 43, 158-64.
108. Shurin M.R., Esche C., Lokshin A., Lotze M.T. (1999): Apoptosis in Dendritic Cells. In A.W. Thomson MTL (ed). Dendritic Cells: Biology and Clinical Applications. San Diego, CA: Academic Press, pp 673-692.
109. Shurin M.R., Pandharipande P.P., Zorina T.D., Haluszczak C., Subbotin V.M., Hunter O., Brumfield A., Storkus W.J., Maraskovsky E., Lotze M.T. (1997). FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol., 179, 174-184.
110. Sietsma H., Nijhof W., Dontje B., Vellenga E., Kamps W.A., Kok J.W. (1998). Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res., 58, 4840-4.
111. Smolle J., Soyer H.P., Ehall R., Bartenstein S., Kerl H. (1986). Langerhans cell density in epithelial skin tumors correlates with epithelial differentiation but not with the peritumoral infiltrate. J Invest Dermatol., 87, 477-9.
112. Speiser D.E., Miranda R., Zakarian A., Bachmann M.F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R.M., Ohashi P.S. (1997). Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med., 186, 645-53.
113. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. (1997). Induction of tolerance by IL-10-treated dendritic cells. J. Immunol., 159, 4772-4780.
114. Steinman R.M. (1991). The dendritic cell system and its role in immunogenecity. Annu. Rev. Immunol., 9, 271-296.
115. Stene M.A., Babajanians M., Bhuta S., Cochran A.J. (1988). Quantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol., 91.125-8.
116. Takano S., Yoshii Y., Rondo S., Suzuki H., Maruno T., Shirai S., Nose T. (1996). Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res., 56, 2185-2190.
117. Tas M., Simons P., Balm F., Drexhage H. (1993). Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol. Immunother., 36, 108-114.
118. Thurnher M., Radmayar C., Ramoner R., Ebner S., Bock G., Klocker H., Romani N., Bartsch G. (1996). Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer, 67, 1-7.
119. Toriyama K., Wen D.R., Paul E., Cochran A.J. (1993). Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol., 100, 269S-273S.
120. Townsend S.E., Allison J.P. (1993). Tumor rejection after direct costimulation of CD8+ T cells by B7- transfected melanoma cells [see comments]. Science. 259, 368-70.
121. Troy A., Davidson P., Atkinson C., Hart D. (1998a). Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer [see comments]. J Urol., 160, 214-9.
122. Troy A.J., Summers K.L., Davidson P.J., Atkinson C.H., Hart D.N. (1998b). Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res., 4, 585-93.
123. Tsujitani S., Furukawa T., Tamada R., Okamura T., Yasumoto K., Sugimachi K. (1987). Langerhans cells and prognosis in patients with gastric carcinoma. Cancer. 59, 501-5.
124. Tsujitani S., Kakeji Y., Watanabe A., Kohnoe S., Maehara Y., Sugimachi K. (1990). Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer. 66, 2012-6.
125. Tuder R.M., Flook B., E., Voelkel N.F. (1995). Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Fit in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Invest., 95, 1798-807.
126. Walker PR., Saas P., Dietrich P.Y. (1998). Tumor expression of Fas ligand (CD95L) and the consequences. Curr Opin Immunol., 10, 564-72.
127. Watanabe S., Sato Y., Kodama T., Shimosato Y. (1983). Immunohistochemical study with monoclonal antibodies on immune response in human lung cancers. Cancer Res., 43, 5883-9.
128. Yamakawa M., Kato H., Takagi S., Karube Y., Seki K., Imai Y. (1993). Dendritic cells in various human thyroid diseases. In Vivo, 7, 249-56.
129. Yamakawa M., Yamada K., Orui H., Tsuge T., Ogata T., Dobashi M., Imai Y. (1995). Immunohistochemical analysis of dendritic/Langerhans cells in thyroid carcinomas. Anal Cell Pathol., 8, 331-43.
130. Young M.R., Wheeler E., Newby M. (1986). Macrophage-mediated suppression of natural killer cell activity in mice bearing Lewis lung carcinoma. J Natl Cancer Inst., 76, 745-50.
131. Zeid N.A., Muller H.K. (1993). S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology, 25, 338-43.